OmaliRel™ (Omalizumab) is a humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It binds to the FcεR1 epitope of human IgE, preventing human IgE from binding to its receptor on mast cells and basophils; thus inhibiting the histamine release response normally triggered by exposure to allergens.

OmaliRel™ is indicated for adult patients with moderate to severe persistent asthma, who have a positive skin test, or, in vitro reactivity to a perennial aeroallergen, or, whose symptoms are inadequately controlled with inhaled corticosteroids. It is indicated for the treatment of adult patients with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment.

OmaliRel™ is available in a kit form with a vial containing the lyophilized product in 150 mg strength. Each kit also contains a sterile WFI vial, syringes, needles and alcohol swabs.